Advertisement
Screener

TRAVERE THERAPEUTICS, INC. (TVTX) Pre-Tax Income

2.8 / 5 stars · 68/120 Roast Me

TRAVERE THERAPEUTICS, INC. Pre-Tax Income

TRAVERE THERAPEUTICS, INC. (TVTX) reported Pre-Tax Income of -$35.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Income Statement

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-04

  • TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$35.00M.
  • TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$36.72M.
  • TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$21.07M.
  • TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was $25.71M.
  • TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$49.27M.
  • TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$320.51M.
  • TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$376.11M.
  • TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$331.15M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 34 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 34 month as first filed
2026-06-30-$35.00M
10-Q · filed 2026-08-04
-$71.72M
10-Q · filed 2026-08-04
-$92.79M
derived: sum of 3 quarters · filed 2026-08-04
-$67.07M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$36.72M
10-Q · filed 2026-05-04
-$57.79M
derived: sum of 2 quarters · filed 2026-05-04
-$32.07M
derived: sum of 3 quarters · filed 2026-05-04
-$44.81M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$21.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$4.65M
derived: sum of 2 quarters · filed 2026-02-19
-$8.09M
derived: sum of 3 quarters · filed 2026-08-04
-$49.27M
10-K · filed 2026-02-19
2025-09-30$25.71M
10-Q · filed 2025-10-30
$12.98M
derived: sum of 2 quarters · filed 2026-08-04
-$28.21M
10-Q · filed 2025-10-30
-$88.55M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$12.73M
10-Q · filed 2026-08-04
-$53.92M
10-Q · filed 2026-08-04
-$114.26M
derived: sum of 3 quarters · filed 2026-08-04
-$169.10M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$41.19M
10-Q · filed 2026-05-04
-$101.53M
derived: sum of 2 quarters · filed 2026-05-04
-$156.36M
derived: sum of 3 quarters · filed 2026-05-04
-$225.93M
derived: sum of 4 quarters · filed 2026-05-04
2024-12-31-$60.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
-$115.18M
derived: sum of 2 quarters · filed 2026-02-19
-$184.74M
derived: sum of 3 quarters · filed 2026-02-19
-$320.51M
10-K · filed 2026-02-19
2024-09-30-$54.84M
10-Q · filed 2025-10-30
-$124.40M
derived: sum of 2 quarters · filed 2025-10-30
-$260.17M
10-Q · filed 2025-10-30
-$348.70M
derived: sum of 4 quarters · filed 2025-10-30
2024-06-30-$69.57M
10-Q · filed 2025-08-06
-$205.33M
10-Q · filed 2025-08-06
-$293.86M
derived: sum of 3 quarters · filed 2025-08-06
-$383.09M
derived: sum of 4 quarters · filed 2025-08-06
2024-03-31-$135.77M
10-Q · filed 2025-05-01
-$224.29M
derived: sum of 2 quarters · filed 2025-05-01
-$313.52M
derived: sum of 3 quarters · filed 2025-05-01
-$415.39M
derived: sum of 4 quarters · filed 2025-05-01
2023-12-31-$88.53M
10-K · filed 2024-02-20
-$177.76M
derived: sum of 2 quarters · filed 2024-10-31
-$279.62M
derived: sum of 3 quarters · filed 2024-10-31
-$376.11M
10-K · filed 2026-02-19
2023-09-30-$89.23M
10-Q · filed 2024-10-31
-$191.10M
derived: sum of 2 quarters · filed 2024-10-31
-$287.58M
10-Q · filed 2024-10-31
-$373.15M
derived: sum of 4 quarters · filed 2024-10-31
2023-06-30-$101.87M
10-Q · filed 2024-08-01
-$85.56M
10-Q · filed 2023-08-03
-$198.35M
10-Q · filed 2024-08-01
-$171.82M
10-Q · filed 2023-08-03
-$283.93M
derived: sum of 3 quarters · filed 2024-08-01
-$367.84M
derived: sum of 4 quarters · filed 2024-08-01
2023-03-31-$96.49M
10-Q · filed 2024-05-06
-$86.25M
10-Q · filed 2023-05-04
-$182.06M
derived: sum of 2 quarters · filed 2024-05-06
-$265.98M
derived: sum of 3 quarters · filed 2024-05-06
-$345.95M
derived: sum of 4 quarters · filed 2024-05-06
2022-12-31-$85.57M
10-K · filed 2024-02-20
-$169.49M
derived: sum of 2 quarters · filed 2024-02-20
-$249.46M
derived: sum of 3 quarters · filed 2024-02-20
-$331.15M
10-K · filed 2025-02-21
-$278.17M
10-K · filed 2023-02-23
2022-09-30-$83.92M
10-K · filed 2024-02-20
-$69.51M
10-Q · filed 2022-10-27
-$163.89M
derived: sum of 2 quarters · filed 2024-02-20
-$245.58M
10-Q · filed 2023-11-07
-$212.41M
10-Q · filed 2022-10-27
-$334.35M
derived: sum of 4 quarters · filed 2024-02-20
2022-06-30-$79.97M
10-K · filed 2024-02-20
-$66.98M
10-Q · filed 2022-08-04
-$142.90M
10-Q · filed 2023-08-03
-$250.43M
derived: sum of 3 quarters · filed 2024-02-20
-$286.03M
derived: sum of 4 quarters · filed 2024-02-20
2022-03-31-$81.69M
10-K · filed 2024-02-20
-$75.92M
10-Q · filed 2022-05-05
-$170.46M
derived: sum of 2 quarters · filed 2024-02-20
-$206.06M
derived: sum of 3 quarters · filed 2024-02-20
-$245.02M
derived: sum of 4 quarters · filed 2024-02-20
2021-12-31-$88.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20
-$124.37M
derived: sum of 2 quarters · filed 2024-02-20
-$163.33M
derived: sum of 3 quarters · filed 2024-02-20
-$216.88M
10-K · filed 2024-02-20
-$179.68M
10-K · filed 2022-02-24
2021-09-30-$35.60M
10-Q · filed 2022-10-27
-$74.56M
derived: sum of 2 quarters · filed 2022-10-27
-$128.11M
10-Q · filed 2022-10-27
-$250.21M
derived: sum of 4 quarters · filed 2022-10-27
2021-06-30-$38.96M
10-Q · filed 2022-08-04
-$92.52M
10-Q · filed 2022-08-04
-$214.61M
derived: sum of 3 quarters · filed 2022-08-04
-$237.14M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$53.55M
10-Q · filed 2022-05-05
-$175.65M
derived: sum of 2 quarters · filed 2022-05-05
-$198.17M
derived: sum of 3 quarters · filed 2022-05-05
-$224.18M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31-$122.09M
10-K · filed 2021-03-01
-$144.62M
derived: sum of 2 quarters · filed 2021-10-29
-$170.62M
derived: sum of 3 quarters · filed 2021-10-29
-$188.79M
10-K · filed 2023-02-23
2020-09-30-$22.53M
10-Q · filed 2021-10-29
-$48.53M
derived: sum of 2 quarters · filed 2021-10-29
-$66.70M
10-Q · filed 2021-10-29
-$96.92M
derived: sum of 4 quarters · filed 2021-10-29
2020-06-30-$26.00M
10-Q · filed 2021-07-29
-$44.17M
10-Q · filed 2021-07-29
-$74.40M
derived: sum of 3 quarters · filed 2021-07-29
-$111.41M
derived: sum of 4 quarters · filed 2021-07-29
2020-03-31-$18.17M
10-Q · filed 2021-05-06
-$48.40M
derived: sum of 2 quarters · filed 2021-05-06
-$85.41M
derived: sum of 3 quarters · filed 2021-05-06
-$124.04M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31-$30.23M
10-K · filed 2021-03-01
-$67.24M
derived: sum of 2 quarters · filed 2021-03-01
-$105.87M
derived: sum of 3 quarters · filed 2021-03-01
-$146.45M
10-K · filed 2022-02-24
2019-09-30-$37.01M
10-K · filed 2021-03-01
-$75.64M
derived: sum of 2 quarters · filed 2021-03-01
-$116.22M
10-Q · filed 2020-11-05
-$123.68M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30-$38.63M
10-K · filed 2021-03-01
-$79.21M
10-Q · filed 2020-07-31
-$86.66M
derived: sum of 3 quarters · filed 2021-03-01
-$140.76M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31-$40.58M
10-K · filed 2021-03-01
-$48.03M
derived: sum of 2 quarters · filed 2021-03-01
-$102.13M
derived: sum of 3 quarters · filed 2021-03-01
-$124.29M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31-$7.46M
10-K · filed 2020-02-24
-$61.56M
derived: sum of 2 quarters · filed 2020-02-24
-$83.72M
derived: sum of 3 quarters · filed 2020-02-24
-$101.87M
10-K · filed 2021-03-01
2018-09-30-$54.10M
10-K · filed 2020-02-24
-$76.26M
derived: sum of 2 quarters · filed 2020-02-24
-$94.41M
10-Q · filed 2019-10-30
-$105.45M
derived: sum of 4 quarters · filed 2020-02-24
2018-06-30-$22.16M
10-K · filed 2020-02-24
-$40.31M
10-Q · filed 2019-08-06
-$51.35M
derived: sum of 3 quarters · filed 2020-02-24
-$70.37M
derived: sum of 4 quarters · filed 2020-02-24
2018-03-31-$18.15M
10-K · filed 2020-02-24
-$29.19M
derived: sum of 2 quarters · filed 2020-02-24
-$48.20M
derived: sum of 3 quarters · filed 2020-02-24
-$63.36M
derived: sum of 4 quarters · filed 2020-02-24
2017-12-31-$11.04M
10-K · filed 2019-02-26
-$11.00K
10-K · filed 2018-02-27
-$30.05M
derived: sum of 2 quarters · filed 2019-02-26
-$45.21M
derived: sum of 3 quarters · filed 2019-02-26
-$58.36M
10-K · filed 2020-02-24
2017-09-30-$19.02M
10-K · filed 2019-02-26
-$34.17M
derived: sum of 2 quarters · filed 2019-02-26
-$47.33M
10-Q · filed 2018-11-01
-$59.61M
derived: sum of 4 quarters · filed 2019-02-26
2017-06-30-$15.15M
10-K · filed 2019-02-26
-$28.31M
10-Q · filed 2018-08-03
-$40.59M
derived: sum of 3 quarters · filed 2019-02-26
-$71.24M
derived: sum of 4 quarters · filed 2019-02-26
2017-03-31-$13.15M
10-K · filed 2019-02-26
-$25.44M
derived: sum of 2 quarters · filed 2019-02-26
-$56.09M
derived: sum of 3 quarters · filed 2019-02-26
-$76.88M
derived: sum of 4 quarters · filed 2019-02-26
2016-12-31-$12.29M
10-K · filed 2018-07-06
-$42.93M
derived: sum of 2 quarters · filed 2018-07-06
-$63.73M
derived: sum of 3 quarters · filed 2018-07-06
-$57.58M
10-K · filed 2019-02-26
2016-09-30-$30.65M
10-K · filed 2018-07-06
-$51.44M
derived: sum of 2 quarters · filed 2018-07-06
-$45.29M
10-Q · filed 2017-11-07
-$58.29M
derived: sum of 4 quarters · filed 2018-07-06
2016-06-30-$20.80M
10-K · filed 2018-07-06
-$14.65M
10-Q · filed 2017-08-09
-$27.64M
derived: sum of 3 quarters · filed 2018-07-06
$116.70M
derived: sum of 4 quarters · filed 2018-07-06
2016-03-31$6.15M
10-K · filed 2018-07-06
-$6.85M
derived: sum of 2 quarters · filed 2018-07-06
$137.49M
derived: sum of 3 quarters · filed 2018-07-06
$111.98M
derived: sum of 4 quarters · filed 2018-07-06
2015-12-31-$12.99M
10-K · filed 2017-03-01
$131.34M
derived: sum of 2 quarters · filed 2017-03-01
$105.83M
derived: sum of 3 quarters · filed 2017-03-01
$105.47M
10-K · filed 2018-07-06
2015-09-30$144.34M
10-K · filed 2017-03-01
$118.83M
derived: sum of 2 quarters · filed 2017-03-01
$118.46M
10-Q · filed 2016-11-04
$89.43M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30-$25.51M
10-K · filed 2017-03-01
-$25.88M
10-Q · filed 2016-08-05
-$54.91M
derived: sum of 3 quarters · filed 2017-03-01
-$72.89M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31-$366.00K
10-K · filed 2017-03-01
-$366.16K
10-Q · filed 2015-05-11
-$29.39M
derived: sum of 2 quarters · filed 2017-03-01
-$47.37M
derived: sum of 3 quarters · filed 2017-03-01
-$38.09M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31-$29.03M
10-K · filed 2015-03-11
-$47.01M
derived: sum of 2 quarters · filed 2016-02-26
-$37.73M
derived: sum of 3 quarters · filed 2016-02-26
-$113.40M
10-K · filed 2017-03-01
-$113.40M
10-K · filed 2015-03-11
2014-09-30-$17.98M
10-K · filed 2016-02-26
-$19.56M
10-Q · filed 2014-11-13
-$8.70M
derived: sum of 2 quarters · filed 2016-02-26
-$84.37M
10-Q · filed 2015-11-06
-$84.16M
10-Q · filed 2014-11-13
-$97.12M
derived: sum of 4 quarters · filed 2016-02-26
2014-06-30$9.28M
10-K · filed 2016-02-26
$5.96M
10-Q · filed 2014-08-14
-$66.39M
10-Q · filed 2015-08-10
-$64.60M
10-Q · filed 2014-08-14
-$79.14M
derived: sum of 3 quarters · filed 2016-02-26
-$91.15M
derived: sum of 4 quarters · filed 2016-02-26
2014-03-31-$75.67M
10-K · filed 2016-02-26
-$70.56M
10-Q · filed 2014-05-15
-$88.42M
derived: sum of 2 quarters · filed 2016-02-26
-$100.43M
derived: sum of 3 quarters · filed 2016-02-26
-$105.35M
derived: sum of 4 quarters · filed 2016-02-26
2013-12-31-$12.75M
10-K · filed 2015-03-11
-$24.76M
derived: sum of 2 quarters · filed 2015-03-11
-$29.68M
derived: sum of 3 quarters · filed 2015-03-11
-$34.55M
10-K · filed 2016-02-26
-$33.75M
10-K · filed 2014-03-28
-$68.16M
10-K/A · filed 2015-07-09
-$67.36M
10-K · filed 2014-03-28
2013-09-30-$12.01M
10-K · filed 2015-03-11
-$10.90M
10-Q · filed 2014-11-13
-$16.93M
derived: sum of 2 quarters · filed 2015-03-11
-$20.69M
10-Q · filed 2014-11-13
2013-06-30-$4.92M
10-K · filed 2015-03-11
-$5.05M
10-Q · filed 2014-08-14
-$9.79M
10-Q · filed 2014-08-14
2013-03-31-$4.87M
10-K · filed 2015-03-11
-$4.87M
10-Q · filed 2014-05-15
2012-12-31-$30.34M
10-K/A · filed 2015-07-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Liquidia Corp (LQDA)United States$6.347B51.23
Erasca, Inc. (ERAS)United States$5.073B-19.96
Veradermics, Inc (MANE)United States$4.839B